The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/ajp.121.8.809

Concerning diazepam, the results of this study are in apparent disagreement with the findings of certain other investigators(2-4). In an activity study of diazepam, good or excellent results were reported in 95% of 103 patients; 50% in a group of 60 patients in the same study subsequently placed on placebo for 1 month showed worsening of symptoms(2 The author appraised the effect of diazepam "as good or excellent if it exerted a positive effect upon symptomatology, as compared with previous agents."

In our double-blind study, each of 3 groups of 14 psychoneurotic patients whose predominant symptom was anxiety received either WY-3498, diazepam, or placebo for a period of 6 weeks. Each patient's condition during and at the termination of medication was judged solely against his condition prior to medication, with no attempt to evaluate the patient's response to diazepam as compared with previous agents. In addition, adjunctive drugs and conventional psychotherapy were not used in this experiment. With this procedural approach, neither diazepam nor WY-3498 had a significantly greater therapeutic effect than placebo, not only in the global ratings of improvement but in the Overall and Gorham BPRS as well.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.